Ritobegron

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ritobegron
Accession Number
DB12080
Type
Small Molecule
Groups
Investigational
Description

Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers).

Structure
Thumb
Synonyms
Not Available
External IDs
KUC-7483
Categories
UNII
LD86RKR53M
CAS number
255734-04-4
Weight
Average: 373.449
Monoisotopic: 373.188922973
Chemical Formula
C21H27NO5
InChI Key
VMMYRRFPMAGXNP-BTYIYWSLSA-N
InChI
InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
IUPAC Name
2-[4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)-2,5-dimethylphenoxy]acetic acid
SMILES
C[[email protected]](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[[email protected]](O)C1=CC=C(O)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Ritobegron.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Ritobegron.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Ritobegron.Approved
AcrivastineRitobegron may decrease the sedative activities of Acrivastine.Approved
AlcaftadineRitobegron may decrease the sedative activities of Alcaftadine.Approved
AlfentanilRitobegron may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
AlgeldrateAlgeldrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
AlimemazineRitobegron may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
AlphacetylmethadolRitobegron may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineRitobegron may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Ritobegron.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Ritobegron.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Ritobegron.Approved
Ammonium chlorideThe serum concentration of Ritobegron can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Ritobegron.Experimental
AntazolineRitobegron may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Ritobegron.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Ritobegron.Approved
AstemizoleRitobegron may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of Ritobegron.Vet Approved
AzatadineRitobegron may decrease the sedative activities of Azatadine.Approved
AzelastineRitobegron may decrease the sedative activities of Azelastine.Approved
BamipineRitobegron may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Ritobegron.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Ritobegron.Investigational
Benzylpenicilloyl PolylysineRitobegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BezitramideRitobegron may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Ritobegron.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Ritobegron.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Ritobegron.Approved, Investigational
BromperidolBromperidol may decrease the stimulatory activities of Ritobegron.Investigational
BrompheniramineRitobegron may decrease the sedative activities of Brompheniramine.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Ritobegron.Investigational
BuclizineRitobegron may decrease the sedative activities of Buclizine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
BuprenorphineRitobegron may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Ritobegron.Experimental
ButorphanolRitobegron may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidRitobegron may decrease the sedative activities of Butyric Acid.Experimental
CabergolineCabergoline may increase the hypertensive activities of Ritobegron.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
CarbinoxamineRitobegron may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilRitobegron may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Ritobegron.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Ritobegron.Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
CetirizineRitobegron may decrease the sedative activities of Cetirizine.Approved
ChloropyramineRitobegron may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineRitobegron may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineRitobegron may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Ritobegron.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
CimetidineRitobegron may decrease the sedative activities of Cimetidine.Approved
CinnarizineRitobegron may decrease the sedative activities of Cinnarizine.Approved
ClemastineRitobegron may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of Ritobegron.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Ritobegron.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Ritobegron.Experimental
ClozapineClozapine may decrease the stimulatory activities of Ritobegron.Approved
CodeineRitobegron may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Ritobegron.Approved
CyclizineRitobegron may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Ritobegron.Approved
CyproheptadineRitobegron may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Ritobegron.Approved
DesipramineDesipramine may increase the stimulatory activities of Ritobegron.Approved
DesloratadineRitobegron may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Ritobegron.Approved
DexbrompheniramineRitobegron may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineRitobegron may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleateRitobegron may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideRitobegron may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneRitobegron may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineRitobegron may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may increase the stimulatory activities of Ritobegron.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
DihydrocodeineRitobegron may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Ritobegron.Approved
DihydroetorphineRitobegron may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineRitobegron may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateRitobegron may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneRitobegron may decrease the sedative activities of Dimetindene.Approved
DimetotiazineRitobegron may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineRitobegron may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateRitobegron may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Ritobegron.Experimental
DosulepinDosulepin may increase the stimulatory activities of Ritobegron.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Ritobegron.Approved
DoxepinRitobegron may decrease the sedative activities of Doxepin.Approved
DoxylamineRitobegron may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPERitobegron may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Ritobegron.Approved
EbastineRitobegron may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Ritobegron.Investigational
EmedastineRitobegron may decrease the sedative activities of Emedastine.Approved
EpinastineRitobegron may decrease the sedative activities of Epinastine.Approved, Investigational
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Ritobegron.Approved
ErgonovineErgonovine may increase the hypertensive activities of Ritobegron.Approved
ErgotamineErgotamine may increase the hypertensive activities of Ritobegron.Approved
EsmirtazapineRitobegron may decrease the sedative activities of Esmirtazapine.Investigational
EthopropazineRitobegron may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Ritobegron.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Withdrawn
EthylmorphineRitobegron may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtorphineRitobegron may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineRitobegron may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Ritobegron.Approved, Illicit, Withdrawn
FentanylRitobegron may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineRitobegron may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Ritobegron.Experimental
FlunarizineRitobegron may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Ritobegron.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Ritobegron.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Ritobegron.Approved, Vet Approved
Glutamic AcidThe serum concentration of Ritobegron can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Ritobegron can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Ritobegron.Approved
HarmalineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Harmaline.Experimental
HeroinRitobegron may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of Ritobegron.Experimental
HydrocodoneRitobegron may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneRitobegron may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
HydroxyzineRitobegron may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Ritobegron.Approved
ImipramineImipramine may increase the stimulatory activities of Ritobegron.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Ritobegron.Withdrawn
Ioflupane I-123Ritobegron may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Ritobegron.Experimental
IproclozideIproclozide may increase the hypertensive activities of Ritobegron.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Ritobegron.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Ritobegron.Approved
IsothipendylRitobegron may decrease the sedative activities of Isothipendyl.Approved
KetobemidoneRitobegron may increase the analgesic activities of Ketobemidone.Approved
KetotifenRitobegron may decrease the sedative activities of Ketotifen.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Ritobegron.Approved
LafutidineRitobegron may decrease the sedative activities of Lafutidine.Investigational
LavoltidineRitobegron may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineRitobegron may decrease the sedative activities of Levocabastine.Approved
LevocetirizineRitobegron may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateRitobegron may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Ritobegron.Approved
LevorphanolRitobegron may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of Ritobegron.Approved
LodoxamideRitobegron may decrease the sedative activities of Lodoxamide.Approved
LofentanilRitobegron may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Ritobegron.Experimental
LoratadineRitobegron may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Ritobegron.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Ritobegron.Approved
MagaldrateMagaldrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Ritobegron.Withdrawn
MeclizineRitobegron may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Ritobegron.Approved
MeptazinolRitobegron may increase the analgesic activities of Meptazinol.Experimental
MepyramineRitobegron may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineRitobegron may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Ritobegron.Approved
MethadoneRitobegron may increase the analgesic activities of Methadone.Approved
Methadyl AcetateRitobegron may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneRitobegron may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
MethenamineThe serum concentration of Ritobegron can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Ritobegron.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Ritobegron.Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Ritobegron.Approved
MetiamideRitobegron may decrease the sedative activities of Metiamide.Experimental
MianserinRitobegron may decrease the sedative activities of Mianserin.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Ritobegron.Approved
MinaprineMinaprine may increase the hypertensive activities of Ritobegron.Approved
MirtazapineRitobegron may decrease the sedative activities of Mirtazapine.Approved
MizolastineRitobegron may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Ritobegron.Approved
MolindoneMolindone may decrease the stimulatory activities of Ritobegron.Approved
MoperoneMoperone may decrease the stimulatory activities of Ritobegron.Experimental
MorphineRitobegron may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Ritobegron.Experimental
NalbuphineRitobegron may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Ritobegron.Withdrawn
NicomorphineRitobegron may increase the analgesic activities of Nicomorphine.Experimental
NizatidineRitobegron may decrease the sedative activities of Nizatidine.Approved
NormethadoneRitobegron may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Ritobegron.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Ritobegron.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
OlopatadineRitobegron may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Ritobegron.Approved
OpipramolOpipramol may increase the stimulatory activities of Ritobegron.Investigational
OpiumRitobegron may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of Ritobegron.Investigational
OxatomideRitobegron may decrease the sedative activities of Oxatomide.Investigational
OxycodoneRitobegron may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneRitobegron may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Ritobegron.Experimental
OzagrelRitobegron may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Ritobegron.Approved
PargylinePargyline may increase the hypertensive activities of Ritobegron.Approved
PemirolastRitobegron may decrease the sedative activities of Pemirolast.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of Ritobegron.Experimental
PentazocineRitobegron may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Ritobegron.Investigational
PerospironePerospirone may decrease the stimulatory activities of Ritobegron.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Ritobegron.Approved
PethidineRitobegron may increase the analgesic activities of Pethidine.Approved
PhenazocineRitobegron may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Ritobegron.Approved
PhenindamineRitobegron may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Ritobegron.Withdrawn
PheniramineRitobegron may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Ritobegron.Approved
PhenoperidineRitobegron may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Ritobegron.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Ritobegron.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Ritobegron.Approved
PipamperonePipamperone may decrease the stimulatory activities of Ritobegron.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Ritobegron.Approved
PiritramideRitobegron may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Ritobegron.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Ritobegron.Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Ritobegron.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
PromethazineRitobegron may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Ritobegron.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Ritobegron.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Ritobegron.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Ritobegron.Approved
QuifenadineRitobegron may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of Ritobegron.Investigational
RanitidineRitobegron may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Ritobegron.Approved
RemifentanilRitobegron may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Ritobegron.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Ritobegron.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Ritobegron.Investigational
Roxatidine acetateRitobegron may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Ritobegron.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
SilodosinSilodosin may decrease the vasoconstricting activities of Ritobegron.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Ritobegron.Approved
SufentanilRitobegron may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Ritobegron.Approved
SultoprideSultopride may decrease the stimulatory activities of Ritobegron.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
TapentadolRitobegron may increase the analgesic activities of Tapentadol.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Ritobegron.Approved
TerfenadineRitobegron may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneRitobegron may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Ritobegron.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of Ritobegron.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Ritobegron.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Ritobegron.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Ritobegron.Approved
ThonzylamineRitobegron may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Ritobegron.Approved
TiaprideTiapride may decrease the stimulatory activities of Ritobegron.Approved, Investigational
TilidineRitobegron may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Ritobegron.Approved
TramadolRitobegron may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastRitobegron may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Ritobegron.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Ritobegron.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Ritobegron.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Ritobegron.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Ritobegron.Experimental
TrimipramineTrimipramine may increase the stimulatory activities of Ritobegron.Approved
TripelennamineRitobegron may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineRitobegron may decrease the sedative activities of Triprolidine.Approved
TritoqualineRitobegron may decrease the sedative activities of Tritoqualine.Experimental
UrapidilUrapidil may decrease the vasoconstricting activities of Ritobegron.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Ritobegron.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Ritobegron.Experimental
Vitamin CThe serum concentration of Ritobegron can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Ritobegron.Approved
ZotepineZotepine may decrease the stimulatory activities of Ritobegron.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Ritobegron.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
ChemSpider
7996631
ChEMBL
CHEMBL2107773
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentOveractive Bladder (OAB)1
3CompletedTreatmentOveractive Bladder1
3WithdrawnTreatmentOveractive Bladder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0103 mg/mLALOGPS
logP1.79ALOGPS
logP0.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.73ChemAxon
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.02 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity103.67 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Phenethylamines / Phenylpropanes / p-Xylenes / Phenoxy compounds / Phenol ethers / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers / Aralkylamines / 1,2-aminoalcohols / Amino acids
show 8 more
Substituents
Phenoxyacetate / Phenethylamine / Phenylpropane / Phenoxy compound / Phenol ether / P-xylene / Xylene / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Phenol
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on October 02, 2017 06:25